BIOTRONIK, a leading manufacturer of medical technology, today announced the European market release of BioMonitor®, a unique implantable cardiac device designed for the highly accurate and reliable monitoring and management of patients with atrial fibrillation (AF) or unexplained syncope.

BioMonitor® is a subcutaneous implantable leadless cardiac monitor for the long-term continuous remote monitoring of patients with arrhythmias such as AF, bradycardia, sudden rate drop, asystole and tachycardia.

As sensitivity and specificity are essential in the detection of arrhythmias such as AF, BIOTRONIK has developed ClearSense Technology with a unique three-vector signal detection that produces highly precise and reliable arrhythmia monitoring.

The ClearSense Technology records three ECG channels converting them to one high quality ECG input signal to clearly distinguish on a beat-to-beat basis between a genuine signal and other artifacts such as myopotentials due to body muscle contractions. This innovative technology allows for optimal arrhythmia detection independent of the device's implant orientation within the body and provides a longevity of 6.4 years.

BioMonitor® is equipped with BIOTRONIK's home monitoring system, which provides daily remote data transfer without patient interaction -- leading to high patient compliance. Its traffic light system streamlines monitoring by highlighting the most relevant information and providing accurate data for physicians to monitor and manage their patients effectively.

"Only long-term continuous monitoring with reliable arrhythmia detection offers the type of vital information necessary for physicians to make the right therapy decisions when managing patients with AF or unexplained syncope," commented Professor Gerhard Hindricks, director of the Department of Electrophysiology at the Leipzig University Heart Center in Germany.

Professor Hindricks together with Professor Wilhelm Haverkamp (Deputy of the Department of Cardiology at Charité Campus Virchow, Humboldt University Berlin), and Professor Dietmar Bänsch (Director of Cardiology Department and Rhythmology at the Rostock University Hospital) are the world's first physicians to implant the BioMonitor® and take advantage of this new approach for monitoring AF in their patients.

"Effective management of AF and unexplained syncope starts with effective monitoring," said Professor Haverkamp. "BioMonitor®, with its ClearSense technology, and BIOTRONIK Home Monitoring® offer the optimal combination of reliability and efficiency."

About BIOTRONIK SE & Co. KGAs one of the world's leading manufacturers of cardiovascular medical devices, with several million devices implanted, BIOTRONIK is represented in over 100 countries by its global workforce of more than 5,600 employees. Known for having its finger on the pulse of the medical community, BIOTRONIK assesses the challenges physicians face, and provides the best solutions for all phases of patient care, ranging from diagnosis to treatment to patient management. Quality, innovation and reliability define BIOTRONIK and its growing success -- and deliver confidence and peace of mind to physicians and their patients worldwide.